Company / Free Cash Flow
CRISPR Therapeutics AG Free Cash Flow History
FY2016-FY2025 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest Free Cash Flow
-$345.9M
FY2025
5-year range
-$532.9M / $457.3M
FY2021-FY2025
Trend
-139.1%
vs FY2024
Sector context
#173 of 192
Health Care
What the data says
Among 192 Health Care companies, CRISPR Therapeutics AG is in the bottom 10% for free cash flow. Free Cash Flow has fluctuated over the past 10 years, ranging from -$533M in FY2022 to $457M in FY2021.
Based on SEC 10-K filings.
-$346M in FY2025.
Declined from -$270M to -$346M over the past 2 years.
Health Care sector context is included.
Free Cash Flow over time
Growth rates
- 3-Year CAGR
- -
- 5-Year CAGR
- -
- 10-Year CAGR
- -
Sector benchmark
Bottom 10% in Health CareTop 90% of 192This company -$345.9M Sector average $474.2M
▼
-173.0% below sector average
Key checks
Key Insights
- In FY2025, free cash flow decreased 139.1% year-over-year.
- Ranks #173 out of 192 companies in the Health Care sector.
- Peak free cash flow was recorded in FY2021.
- Lowest free cash flow in the period was in FY2022.
Company context
Key Data Points
- Low Piotroski F-Score: 1/9 (multiple financial health concerns)
- High earnings quality (cash-backed earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | Free Cash FlowValue | YoY GrowthYoY |
|---|---|---|
| FY2025 | -$345.9M | -139.1% |
| FY2024 | -$144.7M | +46.4% |
| FY2023 | -$269.8M | +49.4% |
| FY2022 | -$532.9M | -216.5% |
| FY2021 | $457.3M | +278.1% |
| FY2020 | -$256.7M | -613.5% |
| FY2019 | $50.0M | +150.5% |
| FY2018 | -$99.0M | -27.1% |
| FY2017 | -$77.9M | -39.4% |
| FY2016 | -$55.9M | -195.9% |
As of FY2025 · SEC 10-K · Updated Feb 28, 2026